NCT00285259 - Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2010

Conditions

Acute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaAcute Myelogenous LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaMyelodysplastic Syndrome

Interventions

BIOLOGICAL

VCL-CB01

5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients

OTHER

Phosphate-buffered Saline (PBS)

1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients

Trial Locations (22)

10021

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center, The Bronx

14263

Roswell Park Cancer Institute Corporation, Buffalo

14642

Strong Memorial Hospital, Rochester

27157

North Carolina Baptist Hosptial, Winston-Salem

30322

Emory University, Atlanta

33612

University of South Florida, Tampa

40202

James Graham Brown Cancer Center, Louisville

48201

Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

60612

Rush University Medical Center, Chicago

60637

University of Chicago, Chicago

66205

University of Kansas Medical Center, Westwood

68198

University of Nebraska Medical Center, Omaha

75246

Baylor University Medical Center, Dallas

75390

University of Texas Southwestern Medical Center at Dallas, Dallas

80218

Rocky Mountain Cancer Center, Denver

85724

Arizona Cancer Center, Tucson

91010

City of Hope National Medical Center, Duarte

02115

Brigham and Women's Hospital, Boston

07601

Hackensack University Medical Center # 408, Hackensack

98109-1024

Fred Hutchinson Cancer Research Center, Seattle